Aurora A plays a dual role in migration and survival of human glioblastoma cells according to the CXCL12 concentration.
Animals
Aurora Kinase A
/ physiology
Brain Neoplasms
/ enzymology
Cell Line, Tumor
Cell Movement
/ drug effects
Cell Survival
Chemokine CXCL12
/ pharmacology
Enzyme Activation
Glioblastoma
/ enzymology
Heterografts
Humans
LIM Domain Proteins
/ biosynthesis
Lateral Ventricles
/ pathology
MAP Kinase Signaling System
Mice
Neoplasm Invasiveness
Neoplasm Proteins
/ physiology
Phosphorylation
Protein Processing, Post-Translational
Receptors, CXCR4
/ physiology
Signal Transduction
Journal
Oncogene
ISSN: 1476-5594
Titre abrégé: Oncogene
Pays: England
ID NLM: 8711562
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
received:
11
03
2018
accepted:
11
07
2018
revised:
10
07
2018
pubmed:
8
8
2018
medline:
12
3
2019
entrez:
8
8
2018
Statut:
ppublish
Résumé
Primary glioblastoma is the most frequent human brain tumor in adults and is generally fatal due to tumor recurrence. We previously demonstrated that glioblastoma-initiating cells invade the subventricular zones and promote their radio-resistance in response to the local release of the CXCL12 chemokine. In this work, we show that the mitotic Aurora A kinase (AurA) is activated through the CXCL12-CXCR4 pathway in an ERK1/2-dependent manner. Moreover, the CXCL12-ERK1/2 signaling induces the expression of Ajuba, the main cofactor of AurA, which allows the auto-phosphorylation of AurA.We show that AurA contributes to glioblastoma cell survival, radio-resistance, self-renewal, and proliferation regardless of the exogenous stimulation with CXCL12. On the other hand, AurA triggers the CXCL12-mediated migration of glioblastoma cells in vitro as well as the invasion of the subventricular zone in xenograft experiments. Moreover, AurA regulates cytoskeletal proteins (i.e., Actin and Vimentin) and favors the pro-migratory activity of the Rho-GTPase CDC42 in response to CXCL12. Altogether, these results show that AurA, a well-known kinase of the mitotic machinery, may play alternative roles in human glioblastoma according to the CXCL12 concentration.
Identifiants
pubmed: 30082913
doi: 10.1038/s41388-018-0437-3
pii: 10.1038/s41388-018-0437-3
pmc: PMC6755987
doi:
Substances chimiques
AJUBA protein, human
0
CXCL12 protein, human
0
CXCR4 protein, human
0
Chemokine CXCL12
0
LIM Domain Proteins
0
Neoplasm Proteins
0
Receptors, CXCR4
0
AURKA protein, human
EC 2.7.11.1
Aurora Kinase A
EC 2.7.11.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
73-87Références
Oncogene. 2000 Oct 5;19(42):4906-16
pubmed: 11039908
Eur J Cell Biol. 2002 Dec;81(12):692-701
pubmed: 12553669
Cancer Res. 2003 Sep 15;63(18):5821-8
pubmed: 14522905
Int J Radiat Oncol Biol Phys. 2004 Jul 15;59(4):928-42
pubmed: 15234026
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Mol Hum Reprod. 2007 Jan;13(1):21-32
pubmed: 17090644
J Cell Biochem. 2008 Jan 1;103(1):245-55
pubmed: 17549698
Mol Cancer Res. 2009 Feb;7(2):157-67
pubmed: 19208739
Mol Pharmacol. 2009 May;75(5):1240-7
pubmed: 19255243
Pathol Res Pract. 2009;205(11):765-73
pubmed: 19616898
PLoS One. 2010 Feb 11;5(2):e9175
pubmed: 20161793
Int J Cancer. 2011 Aug 1;129(3):574-85
pubmed: 20886597
Cancer Res. 2010 Nov 15;70(22):9118-28
pubmed: 21045147
J Cell Sci. 2011 Mar 1;124(Pt 5):679-83
pubmed: 21321325
Cell. 2011 Jul 22;146(2):209-21
pubmed: 21737130
Clin Cancer Res. 2011 Dec 15;17(24):7614-24
pubmed: 22016509
Glia. 2012 Mar;60(3):372-81
pubmed: 22083878
Cell Cycle. 2012 Feb 1;11(3):489-502
pubmed: 22274399
Open Biol. 2013 Mar 20;3(3):120185
pubmed: 23516109
PLoS One. 2013;8(3):e59750
pubmed: 23555768
Mol Cancer Res. 2013 Sep;11(9):1101-11
pubmed: 23761169
Toxicology. 2013 Dec 15;314(2-3):209-20
pubmed: 24157575
J Histochem Cytochem. 2014 Mar;62(3):172-84
pubmed: 24309511
Biochim Biophys Acta. 2014 May;1843(5):934-44
pubmed: 24480460
Biochim Biophys Acta. 2014 May;1843(5):1031-41
pubmed: 24480462
Cancer Chemother Pharmacol. 2014 May;73(5):983-90
pubmed: 24627220
Gene. 2014 Jun 10;543(1):133-9
pubmed: 24680704
Elife. 2014 May 27;3:e02667
pubmed: 24867643
Stem Cell Res. 2014 Jul;13(1):135-43
pubmed: 24879067
Front Cell Neurosci. 2014 May 28;8:144
pubmed: 24904289
Nat Rev Neurosci. 2014 Jul;15(7):455-65
pubmed: 24946761
Neuro Oncol. 2015 Jan;17(1):81-94
pubmed: 25085362
Cancer Res. 2014 Oct 1;74(19):5364-70
pubmed: 25106428
Int J Radiat Oncol Biol Phys. 2014 Nov 15;90(4):886-93
pubmed: 25220720
Neuro Oncol. 2014 Oct;16 Suppl 4:iv1-63
pubmed: 25304271
Mol Cancer Ther. 2015 Feb;14(2):419-28
pubmed: 25522764
J Biol Chem. 2015 Jul 10;290(28):17546-58
pubmed: 25987563
Curr Opin Cell Biol. 2015 Oct;36:23-31
pubmed: 26186729
Oncotarget. 2016 Mar 22;7(12):14259-78
pubmed: 26893360
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Neuro Oncol. 2017 Jan;19(1):66-77
pubmed: 27370398
Target Oncol. 2017 Feb;12(1):11-18
pubmed: 27573024
J Neurooncol. 2017 Jan;131(1):125-133
pubmed: 27644688
Br J Cancer. 2016 Dec 6;115(12):1445-1450
pubmed: 27832665